Michelle C. Kim

Michelle Kim is an attorney in the Intellectual Property Practice Group in the firm's Los Angeles and Orange County offices. 

Areas of Practice

Michelle has represented clients in all aspects of intellectual property, including patent and trademark prosecution, counseling and litigation. Michelle’s patent prosecution experience has included a broad range of technologies, including mechanical and medical devices, pharmaceutical products and delivery devices, immunoassays, various chemical compositions, consumer goods, software and Internet-related devices and methods, as well as aerospace inventions.

Michelle has managed large international patent and trademark portfolio for U.S. and foreign-based clients. She has counseled clients in all aspects of intellectual property, including strategy procurement of intellectual property and due diligence. She has extensive experience opining on the issues of patentability and validity and enforceability of patents, as well as design-around options to avoid infringement of third-party patents.

Prior to practicing law, Michelle was a forensic scientist at the Los Angeles Police Department crime laboratory where she directed the investigation of crime scenes, performed laboratory analyses of evidence and provided expert testimony in criminal cases. Michelle was also an associate scientist at Beckman Instruments (now Beckman Coulter, Inc.) where she was responsible for validating various medical and chemical analyzer instruments. During her undergraduate studies at The Johns Hopkins University, Michelle was involved in research projects involving drug metabolism, immunohistochemical studies involving the brain, and photo-driven electron and energy transfer reactions in inorganic coordination compounds and extended solids.

Articles

• Co-author with Scott Miller, "Avoid Falling Prey to the Pitfalls of the Patent On-Sale Bar," Intellectual Property & Technology Law Journal, December 2010

FDA Law Blog Posts

• Co-author with Peter Reichertz, "Update: Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit," December 16, 2014
• Co-author with Peter Reichertz, "Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit," November 11, 2014
• Co-author with Seth A. Mailhot, "Supreme Court Hears Arguments on "Pay for Delay" Agreements," April 3, 2013